North Carolina specialty pharma company Inspire Pharmaceuticals has announced that it is cutting 27% of its workforce (65 jobs) after its denufosol inhalation solution for the treatment of cystic fibrosis failed a Phase 3 trial. The company says that it will drop pulmonary drug development altogether in order to focus on its opthalmic products. Read the company’s press release.
